Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis

Inclusion Criteria: * Age 11 years and \< 14 years of age. * Signed, witnessed and dated informed consent that is obtained prior to the first study intervention. * Judged to be in good health on the basis of reported medical history. * Plans to remain in the study area for the length of the trial. * All minors have a parent or legal guardian who can read, write and understand English or French. * Pregnancy test to be performed on all female participants at the time of enrollment into the study (prior to day of first immunization visit). Exclusion Criteria: * Pregnancy. * Known or suspected primary disease of the immune system \[conditions suspected of having an immunologic component such as autoimmune diseases (rheumatoid arthritis or inflammatory bowel disease) will not be excluded unless they meet exclusion criterion 3 or are sufficiently clinically active to meet exclusion criterion 5\]. * Malignancy or is receiving immunosuppressive therapy (e.g., daily systemic prednisone ≥ 1 mg/kg would be excluded, participants who are taking topical and inhaled steroids could be included in the study as could participants on a "short course" of oral steroids, 5-7 days, as long as there are not two courses within the previous two week period). * Prior receipt of any pertussis, diphtheria, tetanus or polio containing vaccines, including Hepatitis B vaccine, within the past 5 years. * Any significant underlying chronic disease, including malignancy, cardiopulmonary disease, renal or hepatic dysfunction. * Known impairment of neurologic function or seizure disorder of any etiology. * Personal history of physician diagnosed or laboratory confirmed pertussis disease within the last 2 years. * Receipt of blood products or immunoglobulin within the previous 3 months. * Known or suspected allergy to any of the vaccines intended for use in the study or any of the vaccine components including neomycin, streptomycin and polymyxin B. * Receipt of any vaccine within 2 weeks of receiving a study vaccine. * Daily use of non-steroidal anti-inflammatory drugs.